SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Arcturus Therapeutics Holdings Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

(CUSIP Number)

11/16/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☑ Rule 13d-1(c)
- ☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Meiji Seika Pharma Co., Ltd.	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization JAPAN	
Number of Shares Beneficially	5	Sole Voting Power 2,466,395.00

Owned by Each Reporting Person With:	6	Shared Voting Power 0.00
	7	Sole Dispositive Power 2,466,395.00
	8	Shared Dispositive Power 0.00
9		Aggregate Amount Beneficially Owned by Each Reporting Person 2,466,395.00
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11		Percent of class represented by amount in row (9) 7.88 %
12		Type of Reporting Person (See Instructions) CO

Comment for Type of Reporting Person: With respect to Rows 5 through 9 and Row 11 above, the amounts reported reflect 2,466,395 shares of Common Stock issuable to, and to be held directly by, the Reporting Person.

SCHEDULE 13G

Item 1.

(a) Name of issuer:
Arcturus Therapeutics Holdings Inc.

(b) Address of issuer's principal executive offices:
10285 Science Center Drive, San Diego, California 92121

Item 2.

(a) Name of person filing:
Meiji Seika Pharma Co., Ltd. (the "Reporting Person")

(b) Address or principal business office or, if none, residence:
The address of the principal business office of the Reporting Person is: 2-4-16, Kyobashi, Chuo-ku, Tokyo 104-8002, Japan

(c) Citizenship:
Japan

(d) Title of class of securities:
Common Stock, par value $0.001 per share

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

(a) The information required by this Item 4(a) is set forth in Row 9 of the cover page hereto and is incorporated herein by reference. The number of Shares reported as beneficially owned by the Reporting Person consists of 2,466,395 Shares issuable to, and to be held directly by, the Reporting Person. The percentage reported is based on 28,822,514 Shares outstanding as of November 3, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 5, 2026, plus 2,466,395 Shares issuable to the Reporting Person pursuant to the Securities Purchase Agreement dated November 16, 2026, for a total of 31,288,909 Shares outstanding.

Percent of class:

(b)

7.88 %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

The information required by this Item 4(c)(i) is set forth in Row 5 of the cover page hereto and is incorporated herein by reference.

(ii) Shared power to vote or to direct the vote:

The information required by this Item 4(c)(ii) is set forth in Row 6 of the cover page hereto and is incorporated herein by reference.

(iii) Sole power to dispose or to direct the disposition of:

The information required by this Item 4(c)(iii) is set forth in Row 7 of the cover page hereto and is incorporated herein by reference.

(iv) Shared power to dispose or to direct the disposition of:

The information required by this Item 4(c)(iv) is set forth in Row 8 of the cover page hereto and is incorporated herein by reference.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Meiji Seika Pharma Co., Ltd.

Signature: /s/ Kenshi Murase
Name/Title: Kenshi Murase, Director
Date: 11/16/2026